Abiopharma

🔍 Pizzuti Dana (Executive)

Company: Crinetics Pharmaceuticals, Inc. (CRNX)

Report Date: 2025-08-22

Detailed Transactions and Holdings:

• Acquired 30,000 shares of Common Stock at $16.89 per share (Direct)
  Date: 2025-08-22 | Code: M | equity_swap_involved: false | shares_owned_after: 96,270.00 | transaction_form_type: 4
• Sold 30,000 shares of Common Stock at $30.43 per share (Direct)
  Date: 2025-08-22 | Code: S | equity_swap_involved: false | shares_owned_after: 66,270.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 30,000 shares of Stock Option (Right to Buy) at $16.89 per share (Derivative)
  Date: 2025-08-22 | Code: M | Expires: 2032-10-10 | equity_swap_involved: false | shares_owned_after: 89,042.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 21, 2025.
• F2: The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a volume weighted average sales price of $30.43 per share. The range of sales prices on the transaction date was $30.00 to $30.98 per share. Detailed information on the exact number of shares can be obtained from the Issuer upon request.
• F3: The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.